Email Updates

You are here


PrEP works. Investment in more options must continue, and faster, smarter rollout must be a top priority.

Clinical trials have shown that different types of pre-exposure prophylaxis (PrEP) using antiretroviral (ARVs) drugs dramatically reduce the risk of HIV infection for men and women who take it as directed. While PrEP won’t be right for every individual at risk for HIV, untold numbers of men and women will benefit—if they can access this potentially life-saving option.

So far, PrEP’s implementation has been piecemeal. Meanwhile the landscape is changing as more options move through research, regulatory review or enter the market, intensifying the need to improve implementation.

TDF/FTC is approved for use as oral PrEP in dozens of countries, but PrEP still has not reached many of the people who need it most. Since TDF/FTC (brand name Truvada) was approved in 2012, F/TAF has been approved for men who have sex with men (MSM) and transgender women but not for cisgender women, and cabotegravir has been found to be safe and effective also among MSM and transgender populations. Find more information on cabotegravir on PrEPWatch.

For all these interventions and other ARVs still in the R&D pipeline, advocacy is crucial: There must be continued investment in the development of additional options, community engagement must be integrated from trial design to implementation, and improved programming must support those who need HIV prevention options the most.

Key Update

AVAC welcomes new, additional data that shows an injectable antiretroviral for HIV PrEP is safe and highly effective in reducing HIV risk cisgender men and transgender women who have sex with men.

July 7, 2020
What We're Reading

Educating clients at a San Francisco sexual health clinic about on-demand pre-exposure prophylaxis (PrEP) increased their desire to use the intermittent HIV prevention method, researchers reported this week at the 23rd International AIDS Conference (AIDS 2020: Virtual). Among the 24 percent of clients who did so, the rate of new infections and use of post-exposure prophylaxis (PEP) were low.

July 8, 2020

Taken every 2 months, the long-acting injectable drug cabotegravir (CAB-LA) prevented more HIV infections than daily oral pre-exposure prophylaxis (PrEP) with tenofovir/emtricitabine (TDF/FTC), according to newly announced results from a major Phase 3 study. The results were released originally in May due to the overwhelmingly positive data on CAB-LA for PrEP, but researchers presented their final data in early July at the 23rd International AIDS Conference (AIDS 2020).

July 7, 2020
The BodyPro
Subscribe to RSS - PrEP